Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11655-11668

  Liu, Xing ^a,c   Wang, Xiaofeng ^a,c   Du, Wenzhong ^a,c   Chen, Lingchao ^b   Wang, Guangzhi ^a,c   Cui, Yuqiong ^a,c   Liu, Yang ^a,c   Dou, Zhijin ^a,c   Wang, Hongjun ^a,c   Zhang, Ping ^a,c   Chang, Liang ^a,c   Yi, Liye ^a,c   Cai, Jinquan ^a,c   Jiang, Chuanlu ^a,c  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Chinese Glioma Cooperative Group (CGCG)   (China)

Author keywords

Gli1; Glioma; Hedgehog; Sufu; Temozolomide

Indexed keywords

CYCLOPAMINE; MESSENGER RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR GLI1; DACARBAZINE; GLI1 PROTEIN, HUMAN; REPRESSOR PROTEIN; SMALL INTERFERING RNA; SUFU PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VERATRUM ALKALOID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GLI1 GENE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; MOLECULAR MIMICRY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SUFU GENE; TRANSCRIPTION INITIATION; TUMOR GENE; TUMOR INVASION; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL NUCLEUS; DISEASE COURSE; GLIOMA; METABOLISM; MIDDLE AGED; NUDE MOUSE; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DACARBAZINE; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROGNOSIS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VERATRUM ALKALOIDS;

EID: 84964312658     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2585     Document Type: Article

References (50)

1. Chen L, Zhang W, Yan W, Han L, Zhang K, Shi Z, Zhang J, Wang Y, Li Y, Yu S, Pu P, Jiang C, Jiang T, Kang C. The Putative Tumor Suppressor miR-524-5p Directly Targets Jagged-1 and Hes-1 in Glioma. Carcinogenesis. 2012; 33:2276-2282.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA: a cancer journal for clinicians. 2010; 60:166-193.
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17:98-110.
4. Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine. 2008; 359:492-507.
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell. 2006; 9:157-173.
6. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer research. 2005; 65:5190-5194.
7. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, McKinnon PJ. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene. 2007; 26: 6442-6447.
8. Merchant M, Vajdos FF, Ultsch M, Maun HR, Wendt U, Cannon J, Desmarais W, Lazarus RA, de Vos AM, de Sauvage FJ. Suppressor of fused regulates Gli activity through a dual binding mechanism. Molecular and cellular biology. 2004; 24:8627-8641.
9. Meng X, Poon R, Zhang X, Cheah A, Ding Q, Hui CC, Alman B. Suppressor of fused negatively regulates beta-catenin signaling. The Journal of biological chemistry. 2001; 276:40113-40119.
10. Jenkins D. Hedgehog signalling: emerging evidence for non-canonical pathways. Cellular signalling. 2009; 21:1023-1034.
11. Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, Lv N, Luo S. Suppression of growth and migration by blocking the Hedgehog signaling pathway in gastric cancer cells. Cellular oncology. 2013; 36:421-435.
12. Li ZJ, Nieuwenhuis E, Nien W, Zhang X, Zhang J, Puviindran V, Wainwright BJ, Kim PC, Hui CC. Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis. Development. 2012; 139:4152-4161.
13. Aavikko M, Li SP, Saarinen S, Alhopuro P, Kaasinen E, Morgunova E, Li Y, Vesanen K, Smith MJ, Evans DG, Poyhonen M, Kiuru A, Auvinen A, Aaltonen LA, Taipale J, Vahteristo P. Loss of SUFU function in familial multiple meningioma. American journal of human genetics. 2012; 91:520-526.
14. Pastorino L, Ghiorzo P, Nasti S, Battistuzzi L, Cusano R, Marzocchi C, Garre ML, Clementi M, Scarra GB. Identification of a SUFU germline mutation in a family with Gorlin syndrome. American journal of medical genetics Part A. 2009; 149A:1539-1543.
15. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, et al. Mutations in SUFU predispose to medulloblastoma. Nature genetics. 2002; 31: 306-310.
16. Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-oncology. 2012; 14:1432-1440.
17. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer research. 2008; 68:8733-8742.
18. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A, Delattre JY, Maniotis AJ, Sanson M. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain: a journal of neurology. 2010; 133:973-982.
19. Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC, Ng HK, Chen ZP. Clinical significance of vasculogenic mimicry in human gliomas. Journal of neuro-oncology. 2011; 105:173-179.
20. Min TH, Kriebel M, Hou S, Pera EM. The dual regulator Sufu integrates Hedgehog and Wnt signals in the early Xenopus embryo. Developmental biology. 2011; 358: 262-276.
21. Chen MH, Wilson CW, Li YJ, Law KK, Lu CS, Gacayan R, Zhang X, Hui CC, Chuang PT. Cilium-independent regulation of Gli protein function by Sufu in Hedgehog signaling is evolutionarily conserved. Genes & development. 2009; 23:1910-1928.
22. Cherry AL, Finta C, Karlstrom M, Jin Q, Schwend T, Astorga-Wells J, Zubarev RA, Del Campo M, Criswell AR, de Sanctis D, Jovine L, Toftgard R. Structural basis of SUFU-GLI interaction in human Hedgehog signalling regulation. Acta crystallographica Section D, Biological crystallography. 2013; 69:2563-2579.
23. Lo HW, Zhu H, Cao X, Aldrich A, Ali-Osman F. A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer research. 2009; 69: 6790-6798.
24. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009; 10:459-466.
25. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:2900-2908.
26. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352:997-1003.
27. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell cycle. 2005; 4:1518-1521.
28. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, Butler AP, Gamble J, Gamble S, Hardy C, Hinton J, Jia M, Jayakumar A, et al. Whole exome sequencing of adenoid cystic carcinoma. The Journal of clinical investigation. 2013; 123:2965-2968.
29. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting Sufu and Fus-1 expression. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:20350-20355.
30. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG. Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nature genetics. 2007; 39:259-263.
31. Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, Jin W, Zhang Y. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer research. 2013; 73:6046-6055.
32. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes & development. 2001; 15:1311-1333.
33. Bogler O, Mikkelsen T. Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. Journal of cellular biochemistry. 2005; 96:16-24.
34. Paul P, Volny N, Lee S, Qiao J, Chung DH. Gli1 transcriptional activity is negatively regulated by AKT2 in neuroblastoma. Oncotarget. 2013; 4:1149-1157.
35. Kenney AM, Rowitch DH. Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Molecular and cellular biology. 2000; 20:9055-9067.
36. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer research. 2002; 62:4773-4780.
37. Liao X, Siu MKY, Au CWH, Wong ESY, Chan HY, Ip PPC, Ngan HYS, Cheung ANY. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis. 2008; 30:131-140.
38. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G, Philpott MP, Aberger F. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Molecular and cellular biology. 2006; 26:6283-6298.
39. Chen JS, Huang XH, Wang Q, Huang JQ, Zhang LJ, Chen XL, Lei J, Cheng ZX. Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. 2013; 34:10-19.
40. Mazumdar T, DeVecchio J, Agyeman A, Shi T, Houghton JA. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget. 2011; 2:638-645.
41. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer research. 2005; 65:7573-7579.
42. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer research. 2009; 29:4845-4854.
43. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010; 17:510-522.
44. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell. 2011; 19:17-30.
45. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer research. 2009; 69:9065-9072.
46. Chen PC, Cheng HC, Wang J, Wang SW, Tai HC, Lin CW, Tang CH. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget. 2014; 5:1595-1608.
47. Wang L, Shi ZM, Jiang CF, Liu X, Chen QD, Qian X, Li DM, Ge X, Wang XF, Liu LZ, You YP, Liu N, Jiang BH. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 2014; 5:5416-5427.
48. Thomas D, Schmittgen KJL. Analyzing real-time PCR data by the comparative CT method. Nature protocols. 2008; 3:1101-1108.
49. Wang H, Jiang C. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma. Oncology reports. 2013; 30: 2350-2356.
50. Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ, Chen LC, Lei XH, Sun X, Liu X, Wang HB, Li XF, Yang DB Sun Y, Zhao ZF, Jiang T, Li YL, et al. Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo. CNS neuroscience & therapeutics. 2013; 19:926-936.